Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBloomsbury Regulatory News (BMY)

Share Price Information for Bloomsbury (BMY)

Share Price is delayed by 15 minutes
Get Live Data
665.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 2.00 (0.301%)
Market Cap: £541.28m
BMY Live PriceLast checked at - London Stock Exchange

Intraday Bloomsbury Share Chart

Acquisition

2 Jun 2021 12:17

RNS Number : 6090A
Bloomsbury Publishing PLC
02 June 2021
 

BLOOMSBURY PUBLISHING PLC

("Bloomsbury" or "the Company")

Bloomsbury acquisition strengthens Consumer division: Acquisition of Head of Zeus Limited

 2 June 2021

Bloomsbury Publishing Plc (LSE: BMY), the leading independent publisher, today announces that it has completed the acquisition of the issued share capital of Head of Zeus Limited ("Head of Zeus", "HoZ" or the "Acquisition"). The total valuation is £8.45 million, including payments of pre-existing loans. The consideration, net of pre-existing loans, is £7.35 million, of which £5.5 million will be satisfied in cash at completion, with £1.1 million payable in cash post completion, subject to working capital and other considerations, and £0.75 million of deferred consideration payable in cash subject to achievement of revenue, profit and Netflix release targets.

Head of Zeus is an independent publisher of genre fiction and narrative non-fiction and children's books, based in London. It has published many bestsellers, won literary prizes and industry awards. Its best-selling authors include Dan Jones, Cixin Liu, Victoria Hislop, and Lesley Thomson, and Elodie Harper, whose The Wolf Den went last week to number 5 in The Times bestseller list. Cixin Liu's bestselling science fiction trilogy, The Three-Body Problem, is being adapted for Netflix by David Benioff and D.B. Weiss, creators of HBO's Game of Thrones.

This acquisition will provide a strong addition to Bloomsbury's thriving Consumer division and support our long term Consumer growth strategy, with new high quality authors and effective publishing across all formats, including e-book and audio.

HoZ generated £8.6 million* of revenue in the year ended 31 December 2020, and profit before tax of £0.3 million*, with net assets of £4.6 million*.

Nigel Newton, Chief Executive of Bloomsbury, commented:

"Head of Zeus's entrepreneurial and innovative approach to publishing, and its wide range of trade titles, will make a strong addition to Bloomsbury's own. Bloomsbury will be able to provide the scale and digital platforms to boost Head of Zeus' success while operating as an independent imprint within the Bloomsbury Consumer division. We look forward to welcoming Head of Zeus' great authors and talented staff to Bloomsbury and working with them in the years to come."

Anthony Cheetham, Chairman, Head of Zeus commented:

"After nine vigorous years as an independent publisher, I believe that Head of Zeus, our authors, our staff and our shareholders have found the right long term home for our company with Bloomsbury.

I have known Nigel Newton for more than thirty years. We share many of the same values: creative publishing, unique content and beautiful books. And an entrepreneurial spirit that values innovation above conformity. Bloomsbury Publishing Plc is itself unique as the only British book publisher listed on the London Stock Exchange.

I would like to express my gratitude to all our stakeholders for their support since Head of Zeus was launched in 2012, and my thanks to Bloomsbury for opening the door to further growth and opportunity in the years ahead."

*Audited.

 

For further information, please contact:

Bloomsbury Publishing Plc

 

Nigel Newton, Chief Executive

nigel.newton@bloomsbury.com

Penny Scott-Bayfield, Group Finance Director

penny.scott-bayfield@bloomsbury.com

Hudson Sandler

+44 (0) 20 7796 4133

Dan de Belder / Rebekah Chapman

bloomsbury@hudsonsandler.com

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

The information in this announcement has not been audited or otherwise independently verified and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. None of the Company or any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss whatsoever arising from any use of this announcement, or its contents, or otherwise arising in connection with this announcement.

This announcement does not constitute or form part of any offer or invitation to sell, or any solicitation of any offer to purchase any shares in the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment or investment decisions relating thereto, nor does it constitute a recommendation regarding the shares of the Company.

Certain statements, statistics and projections in this announcement are or may be forward looking. By their nature, forward‑looking statements involve a number of risks, uncertainties or assumptions that may or may not occur and actual results or events may differ materially from those expressed or implied by the forward-looking statements. Accordingly, no assurance can be given that any particular expectation will be met and reliance should not be placed on any forward-looking statement. Accordingly, forward-looking statements contained in this announcement regarding past trends or activities should not be taken as representation that such trends or activities will continue in the future. You should not place undue reliance on forward-looking statements, which are based on the knowledge and information available only at the date of this announcement's preparation.

The Company does not undertake any obligation to update or keep current the information contained in this announcement, including any forward‑looking statements, or to correct any inaccuracies which may become apparent and any opinions expressed in it are subject to change without notice.

References in this announcement to other reports or materials, such as a website address, have been provided to direct the reader to other sources of information on Bloomsbury Publishing Plc which may be of interest. Neither the content of Bloomsbury's website nor any website accessible by hyperlinks from Bloomsbury's website nor any additional materials contained or accessible thereon, are incorporated in, or form part of, this announcement.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQUUAARAOUNRAR
Date   Source Headline
1st Jun 20185:03 pmRNSDirector/PDMR Shareholding
22nd May 20187:00 amRNSFinal Results
18th May 20183:23 pmRNSBlock Listing Six Monthly Return
8th May 20187:00 amRNSBloomsbury and Spotify announce partnership
1st May 20186:25 pmRNSAcquisition of IB Tauris & Co. Limited
1st May 20187:00 amRNSAcquisition of IBT Tauris & Co. Limited
19th Apr 20187:00 amRNSBoard Appointment
19th Mar 20184:37 pmRNSTrading Update
21st Dec 20177:00 amRNSDirectorate Change
17th Nov 201711:44 amRNSBlock listing Interim Review
2nd Nov 201712:25 pmRNSHolding(s) in Company
24th Oct 20177:00 amRNSHalf-year Report
2nd Oct 20173:22 pmRNSHolding(s) in Company
22nd Sep 20177:00 amRNSInterim Results Date Change
5th Sep 20174:57 pmRNSDirector/PDMR Shareholding
11th Aug 20172:24 pmRNSDirector/PDMR Shareholding
28th Jul 201712:56 pmRNSDirector/PDMR Shareholding
28th Jul 201712:54 pmRNSDirector/PDMR Shareholding
28th Jul 201712:54 pmRNSDirector/PDMR Shareholding
28th Jul 201712:52 pmRNSDirector/PDMR Shareholding
20th Jul 20177:00 amRNSDirector/PDMR Shareholding
18th Jul 20171:19 pmRNSResults of voting on resolutions at the AGM
18th Jul 20177:00 amRNSTrading Statement
4th Jul 20172:45 pmRNSDirector/PDMR Shareholding
19th Jun 20179:55 amRNSAnnual Financial Report
16th Jun 20177:00 amRNSBoard Appointment
19th May 20174:44 pmRNS6 Month Blocklisting Return
18th May 20177:00 amRNSFinal Results
23rd Mar 20171:47 pmRNSHolding(s) in Company
20th Jan 20177:00 amRNSBoard Appointment
4th Jan 20177:15 amRNSEmployee Benefit Trust purchase of shares
13th Dec 20164:53 pmRNSDirector/PDMR Shareholding
13th Dec 20164:52 pmRNSDirector/PDMR Shareholding
13th Dec 20164:50 pmRNSDirector/PDMR Shareholding
13th Dec 20164:46 pmRNSDirector/PDMR Shareholding
18th Nov 201610:35 amRNSBlock Listing Six Monthly Return
1st Nov 20164:08 pmRNSHolding(s) in Company
1st Nov 20162:58 pmRNSHolding(s) in Company
27th Oct 20167:00 amRNSHalf-year Report
4th Oct 20164:35 pmRNSPrice Monitoring Extension
12th Sep 20164:30 pmRNSPro forma historic results
31st Aug 20163:09 pmRNSTotal Voting Rights
23rd Aug 20162:14 pmRNSApplication for Admission
16th Aug 20169:55 amRNSHolding(s) in Company
19th Jul 20161:24 pmRNSResults of voting on resolutions at the AGM
18th Jul 20163:15 pmRNSHolding(s) in Company
13th Jul 20167:00 amRNSCapital Markets Day and Business Update
4th Jul 20165:31 pmRNSHolding(s) in Company
24th Jun 20162:43 pmRNSAnnual Financial Report
9th Jun 201612:43 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.